Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer - Concepedia

Concepedia

Publication | Closed Access

Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer

644

Citations

11

References

2003

Year

Matthew R. Smith, James A. Eastham, Donald M. Gleason, Daniel Shasha, Simon Tchekmedyian, Norman R. Zinner

The Journal of Urology

Abstract

Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer.

References

	Year	Citations

Page 1